20 articles
A phase III trial of 408 men finds metformin does not delay prostate cancer progression during active surveillance — and may worsen outcomes in obese patients.
Clinical trial tested whether metformin could improve surgical outcomes and reduce hospital stays in non-diabetic older patients.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
Six-month trial examines whether metformin treatment can improve telomere length and longevity gene expression in prediabetic individuals.
A 1.6-million-person cohort study finds metformin neither prevents AMD development nor slows progression to advanced disease stages.
Columbia University tested whether the diabetes drug metformin could slow memory loss in people with mild cognitive impairment.
Wake Forest study explores whether the diabetes drug metformin can trigger cellular changes linked to longevity in healthy people.
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
Clinical trial tested whether metformin could enhance resistance training benefits for muscle mass and strength in older adults.
Six-month trial finds diabetes drug metformin significantly reduces knee pain compared to placebo in people with osteoarthritis and excess weight.
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.
Four-year study examined whether metformin could protect blood vessels in people with metabolic syndrome beyond its diabetes benefits.
A major review challenges the evidence behind metformin as a longevity drug, exposing methodological flaws in landmark studies.
A massive 860,000-patient multinational study finds metformin users face significantly lower delirium and mortality risk than those on DPP-4 inhibitors.
University of Pennsylvania researchers investigated how insulin resistance and testosterone interact in women after menopause.
Small trial tested whether the diabetes drug metformin could enhance immune response to pneumonia vaccine in aging adults.
New study reveals metformin's anti-aging effects depend entirely on whether you're insulin resistant or sensitive.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
Small trial tests whether diabetes drug metformin can enhance immune response to flu vaccination in aging adults.
